- Home
- ACXP vs AEON Comparison
ACXP vs AEON Comparison
Compare ACXP & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- AEON
- Stock Information
- Founded
- ACXP 2017
- AEON N/A
- Country
- ACXP United States
- AEON United States
- Employees
- ACXP N/A
- AEON N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- AEON Health Care
- Exchange
- ACXP Nasdaq
- AEON Nasdaq
- Market Cap
- ACXP 31.4M
- AEON 36.4M
- IPO Year
- ACXP 2021
- AEON N/A
- Fundamental
- Price
- ACXP $1.77
- AEON $0.61
- Analyst Decision
- ACXP Strong Buy
- AEON Strong Buy
- Analyst Count
- ACXP 1
- AEON 1
- Target Price
- ACXP $12.00
- AEON $5.00
- AVG Volume (30 Days)
- ACXP 35.4K
- AEON 90.7K
- Earning Date
- ACXP 11-12-2024
- AEON 11-13-2024
- Dividend Yield
- ACXP N/A
- AEON N/A
- EPS Growth
- ACXP N/A
- AEON N/A
- EPS
- ACXP N/A
- AEON N/A
- Revenue
- ACXP N/A
- AEON N/A
- Revenue This Year
- ACXP N/A
- AEON N/A
- Revenue Next Year
- ACXP N/A
- AEON N/A
- P/E Ratio
- ACXP N/A
- AEON N/A
- Revenue Growth
- ACXP N/A
- AEON N/A
- 52 Week Low
- ACXP $1.52
- AEON $0.60
- 52 Week High
- ACXP $5.28
- AEON $17.17
- Technical
- Relative Strength Index (RSI)
- ACXP 31.97
- AEON 28.19
- Support Level
- ACXP $1.82
- AEON $0.65
- Resistance Level
- ACXP $1.89
- AEON $0.88
- Average True Range (ATR)
- ACXP 0.08
- AEON 0.07
- MACD
- ACXP -0.00
- AEON -0.03
- Stochastic Oscillator
- ACXP 17.39
- AEON 1.75
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.